Corvus Pharmaceuticals (NASDAQ:CRVS) Rating Lowered to “Sell” at Wall Street Zen

Corvus Pharmaceuticals (NASDAQ:CRVS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

CRVS has been the topic of several other research reports. Mizuho set a $30.00 price target on Corvus Pharmaceuticals in a report on Thursday, January 29th. HC Wainwright boosted their price objective on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, January 21st. Jefferies Financial Group raised their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Barclays raised their target price on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Corvus Pharmaceuticals Stock Down 4.3%

CRVS opened at $15.32 on Friday. The company’s 50-day moving average price is $16.46 and its 200 day moving average price is $10.60. Corvus Pharmaceuticals has a fifty-two week low of $2.54 and a fifty-two week high of $26.95. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -30.64 and a beta of 0.79.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, March 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Research analysts anticipate that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. MPM Bioimpact LLC acquired a new stake in Corvus Pharmaceuticals during the fourth quarter valued at approximately $21,126,000. State Street Corp boosted its holdings in Corvus Pharmaceuticals by 177.1% during the fourth quarter. State Street Corp now owns 2,788,223 shares of the company’s stock worth $21,469,000 after buying an additional 1,781,904 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Corvus Pharmaceuticals in the second quarter worth approximately $5,754,000. Geode Capital Management LLC grew its position in Corvus Pharmaceuticals by 130.7% in the second quarter. Geode Capital Management LLC now owns 1,361,740 shares of the company’s stock worth $5,448,000 after buying an additional 771,454 shares during the last quarter. Finally, DCF Advisers LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter valued at $5,613,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals News Roundup

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $33 (from $32), implying substantial upside from current levels — a clear analyst vote of confidence that can support longer‑term buying interest. Oppenheimer Rating/Price Target
• Positive Sentiment: Company announced positive safety and efficacy data from cohort 4 of soquelitinib in a Phase 1 atopic dermatitis trial, including responses in patients with prior systemic therapy — this clinical progress materially de‑risks the program and supports future value for the pipeline. Atopic Dermatitis Trial Data
• Neutral Sentiment: Corvus released its Q4 2025 results and held an earnings call; management highlighted strategic advances tied to the pipeline and provided a business update, but the call materials are a mixed read for near‑term revenue prospects. Earnings Call Highlights
• Negative Sentiment: Q4 EPS came in at ($0.15), missing consensus by $0.01 — a small miss but enough to pressure sentiment in the absence of immediate revenue drivers; this likely contributed to the intraday pullback. Earnings Miss / Transcript
• Neutral Sentiment: Reported short‑interest updates in recent days show anomalous/zero values and appear unreliable — there is no clear evidence of a near‑term short squeeze or meaningful short pressure based on the published figures. (No actionable link available.)

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.